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URINARY EXCRETION OF EPINEPHRINE AND DOPAMINE CORRELATES
WITH EFFICIENCY OF G-CSF MOBILIZED STEM CELLS IN PATIENTS
WITH AL AMYLOIDOSIS
Landau, H.J.1, Bello, C.1, Hoover, E.1, Riedel, E.1, Frenette, P.2,
Comenzo, R.L.3 1Memorial Sloan-Kettering Cancer Center, New York,
NY; 2Albert Einstein College of Medicine, Bronx, NY; 3Tufts Medical
Center, Boston, MA
Introduction:Hematopoietic stem cell (HSC)migration is essential
for peripheral blood HSC collection. Sympathetic signaling regu-
lates HSC egress from bone marrow. Ablation of adrenergic trans-
mission in animal models indicates that norepinephrine (NE)
controls G-CSF-induced HSC mobilization (Cell 2006). b adrener-
gic agonists and antagonists enhance and reduce HSC mobilization,
respectively. We prospectively studied catecholamines and the effi-
ciency of HSC collection in patients (pts) with AL amyloidosis un-
dergoing G-CSF mobilization prior to high dose melphalan and
HSC rescue on a phase II study.
Methods: 24h urine samples were analyzed for epinephrine (EPI),
NE and dopamine (DA) excretion before G-CSF administration
and after HSC collection was completed. Statistics included Spear-
man rank coefficient (r), Wilcoxon rank sum and Signed rank tests.
Results: In 39 pts median (med) CD34 cells collected was 8.3 x 106/
kg (IQR 5,12.3) in a med of 2 (IQR 2,3) collections. The med CD34
cells infused on day 0 was 4.7 x 106/kg (IQR 3.8, 6) and time to neu-
trophil engraftment (ANC. 500 x 2 days) was 9 days (IQR 9, 11).
Baseline urinary excretion of EPI and DA correlated with total
CD34 cells collected (r5 0.33, P5 0.005; r5 0.47, P5 0.05, respec-
tively). An optimal collection defined as 5 x 106 CD34 cells/kg in 2
collections was achieved by 25/39 pts and was associated with higher
baseline EPI (7 vs 4mcg/24h, P5 0.02) andDA (220 vs 156mcg/24h,
P5 0.05) but not NE. Only DA significantly changed from baseline
to after HSC collection (P #0.0001).
Conclusion: Sympathetic signals regulate HSC egress from their
niche, and we found baseline EPI and DA excretion are associated
with greater and more efficiently collected HSCs following G-CSF
in pts with AL amyloidosis. In mouse models G-CSF mobilization
requires peripheral adrenergic signals and reduces NE in bone
(Cell 2006). Reduced DA excretion following G-CSF in our study
may indicate that circulating catecholamines serve as markers for
overall sympathetic tone and could possibly predict mobilization ef-
ficiency in humans. These data support other evidence that DA plays
a role in progenitor migration (Nat Immunol. 2007) and indicates
that DA is important inG-CSFmobilization in pts with AL amyloid-
osis. Modulation of the sympathetic system to enhance HSC mobi-
lization and the use of catecholamine values to guide clinicians with
respect to the need for plerixafor or chemo-mobilization should be
explored.132
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Background: Limited therapeutic options exist for patients with
multiple myeloma (MM) relapsing after initial autologous hemato-
poietic stem cell transplantation (HSCT). A second autologous
HSCT using a different conditioning regimen may provide long-
term disease control. We report the pharmacokinetics and safety
of daily intravenous (IV) busulfan (Bu) conditioning given with bor-
tezomib for autologous HSCT from a multicenter, prospective
Phase 2 study.
Methods: 30 patients with relapsed MM who had a first autologous
HSCT $1 year prior to the planned HSCT were enrolled from
eleven centers in the US and Canada. Patients received a test dose
of IV Bu (0.8 mg/kg) over 2 hours between Days -12 and -9 prior
to HSCT. Blood samples were drawn for pharmacokinetic (PK)
analysis and Bu exposure was determined as area under the concen-
tration-time curve (AUC). Individualized Bu PK-directed dosing for
the conditioning regimen was recommended to achieve a total regi-
men AUC of 20,000 mM$min. IV Bu was administered over 3 hours
once daily from Day -5 to Day -2. Confirmatory PK analysis was
conducted in all patients on Day -5. Bu doses were adjusted on
Days -3 and -2, if needed. Bortezomib (1.3 mg/m2 QD) was admin-
istered as an IV bolus injection on Day -1.
Results: PK testing with 0.8 mg/kg of IV Bu dose revealed that
40.0% (n 5 12/30) of patients had doses outside the expected range
(1,250 mM$min +/- 20%). PK-directed daily Bu dose on the first day
of conditioning (Day -5) ranged between 1.99 and 4.73 mg/kg (94.6
and 213.4 mg/m2). Subsequent dosing based on test PK resulted in
93.3% of patients (n 5 28/30) falling within the target range
(AUC, 20,000 mM$min +/-20%), underscoring the utility of test
PK in achieving optimal dosing during conditioning.Mean Bu clear-
ance for test dose and on Day -5 were comparable, 3.03 and 2.93 ml/
min/kg, respectively. Two patients (6.7%) needed dose reduction on
Days -3 and -2. No instances of VOD, seizure, or worsening neurop-
athy have been reported to date. Grade 3 or higher stomatitis was ob-
served in 23% of patients (n5 7/30). One death occurred on Day 30
after transplant in a patient with Parkinsonism who died of pulmo-
nary complications.
Conclusion: Pre-transplant test dose PK analysis allows accurate
targeting of IV busulfan dosing in more than 90% of patients. The
conditioning regimen of bortezomib and IV busulfan with PK-di-
rected dose optimization is well-tolerated in patients with relapsed
MM who undergo second autologous HSCT.133
STEM CELL MOBILIZATION FAILURES SALVAGED WITH PLERIXAFOR:
LONG TERM FOLLOW UP OF ENGRAFTMENT AND OUTCOMES
Deol, A., Abrams, J., Al-Kadhimi, Z., Abidi, M., Ayash, L., Lum, L.G.,
Ratanatharathorn, V., Uberti, J. Wayne State University/Karmanos
Cancer Institute, Detroit, MI
We enrolled 49 pts in a compassionate use protocol to mobilize
stem cells(SC) for pts who failed a mobilization attempt. Pts received
0.24 mg/kg of Plerixafor (P) sq 9 -11 hrs prior to apheresis in addi-
tion to BID GCSF. Table 1 shows pt demographics. Using P and
GCSF,$ 2.5 x 106 CD34+ cells/Kg were collected in 33 pts (67%).
Table.
Patient Demographics ResultsMedian Age 64 (23-74) years
DiagnosisNon Hodgkin Lymphoma 27 Pts ( 55%)
Multiple Myeloma 17 Pts (35%)
Hodgkin Lymphoma 5 Pts (10%)# of Previous mobilization Attempts
1 37 Pts (76%)
$ 2 12 Pts (24%)
S254 Poster Session IThe median days for pheresis was 1 day (range, 1-3). The median
SC dose collected was 4 x 106 CD34+ cells/ Kg (range, 2.5 – 14.3).
The median CD-34+ peripheral blood count on the 1st day collec-
tion with P was 22.4/uL. In contrast the median peripheral blood
CD-34+ cell count on the day of failed collection was 6.2 /uL. The
average increase using P was 14.9 CD-34+ cells/uL. We collected
$ 2.5 x 106 CD34+ cells/Kg on 4/5 pts with HD, 13/17 pts with
MM and 16/27 pts with NHL. 16 pts (33%) collected\ 2.5 x 106
CD34+ cells/Kg, with median cell dose of 1.4 x 106 CD34+ cells/
Kg (range, 0.4-2.2). The median number of days of pheresis was 2
days (range, 1-4). For these16 pts the median CD-34+ count on
the day of unsuccessful collection was11.2 /uL, compared to 8.3/
uL with use of P and GCSF. The common side effects attributed
to P were diarrhea, fatigue, thrombocytopenia and bone pain; ob-
served in 12%, 8%, 8% and 6% pts, respectively. 43/ 49 pts pro-
ceeded to an autologus SC transplant, 34 pts received $ 2.5 x 106
CD34+ cells/Kg. Thirty two of these pts used the P collection as
the only source of SC. Two pts had their P mobilized SC combined
with a previous suboptimal SC collection. Nine pts received\2.5 x
106 CD34 + cells/Kg; 4 pts received P mobilized SC alone, 5 pts re-
ceived P mobilized SC combined with their previously mobilized
SC. All pts received GCSF from day +6 till WBC engraftment.
The median days of WBC and platelet engraftment were day +11
(range, 9-13 days) and day +16 (range, 11-77 days), respectively.
With a median follow up of 13.7 months, long term engraftment
data is available on 27 pts. The median white cell count, hemoglobin
and platelet count 1 year after transplant was 4.7 x 109/L, 12.2 g/dL
and 109 x109/L, respectively. To date 15 pts have evidence of disease
progression. Two patients have developed MDS/AML post trans-
plant. Failure to increase peripheral CD34 count after P when com-
pared to previous attempts may predict unsuccessful mobilization.
P is well tolerated with minimal side effects, acceptable time to en-
graftment and acceptable peripheral blood counts at 1 yr after the
transplant.134
OUTCOMES FOLLOWING SALVAGE AUTOLOGOUS STEM CELL TRANS-
PLANT (SCT) FOR MULTIPLE MYELOMA
Silva Rondon, C., Hassoun, H., Chimento, D., Jia, X., Giralt, S.,
Landau, H.J. Memorial Sloan-Kettering Cancer Center, New York, NY
Background: High-dose therapy and SCT has improved the pro-
gression-free (PFS) and overall survival (OS) of patients with multi-
ple myeloma (MM). However all patients eventually develop disease
recurrence. In the era of effective novel agents (such as bortezomib,
lenalidomide and thalidomide), the optimal salvage strategy is unde-
fined.
Methods: We retrospectively analyzed the outcomes of patients
who underwent salvage melphalan-based SCT for relapsed MM at
Memorial Sloan-Kettering Cancer Center.
Results: Between 1995 and 2011, 60 patients with MM received an
initial SCT and then second autograft for relapsed disease at our cen-
ter. Conditioning regimen consisted of melphalan 100 (N 5 9), 140
(N5 20) or 200mg/m2 (N5 31). Themedian age at 2nd SCTwas 59
years (range 36-75) and 58% (N 5 35) were male. At the time of 1st
and 2nd transplant, 14% (5/36) and 36% (14/39) of patients whowere
assessed with either karyotype or FISH had high risk cytogenetics
(including t (4;14), +1q, p53 loss, or del 13q by karyotype), respec-
tively. Median interval between first and salvage SCT was 32 mos
(range 7.1-88.7). Of evaluable patients, 78% (46/59) had chemother-
apy sensitive disease prior to salvage SCT and 22% were chemore-
sistant. Twenty-eight patients received maintenance following
salvage SCT, most often IMID-based, while 11 went on to receive
an allogeneic SCT, 3/11 patients were received maintenance prior
to allogeneic SCT. Response was assessed at 2-3 mos post-SCT
and 77% of evaluable patients achieved . 5 partial response (PR),
16% had stable disease (SD), and 7% progressed despite salvage
SCT. Following salvage SCT, 23 patients received maintenance
therapy and 11 went on to allogeneic SCT. The median PFS follow-
ing second autograft was 11.2 mos (95% CI: 7.6-14.5); the median
OS was 24 mos (95% CI: 19-42). Although the numbers were small,
high-risk cytogenetics, the interval from first to second SCT, che-
mosensitivity, response and whether patients received maintenancetherapy or allogeneic SCT following salvage autologous SCT did
not significantly impact PFS or OS in this data set.
Conclusions: Salvage SCT is an effective strategy for relapsed MM
following initial autograft and results in responses in the majority of
patients. Although OS and PFS following salvage SCT is similar to
other salvage strategies, novel conditioning regimens and/or effec-
tive maintenance strategies may improve this approach.135
THE ROLE OF HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY
INDEX (HCT-CI) IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR
MULTIPLE MYELOMA
Lazaryan, A.1, Bolwell, B.1, Rybicki, L.2, Reu, F.1, Dean, R.1,
Duong, H.1, Sobecks, R.1, Tench, S.1, Copelan, E.1, Kalaycio, M.1
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Both autologous stem cell transplantation (ASCT) and novel
agents have improved outcomes for patients (pts) with multiple my-
eloma (MM). ASCT is often restricted to fitter pts due to concerns of
excessive treatment-related morbidity and mortality. Pre-transplant
risk-stratification based on comorbidity index (CI) has been recog-
nized as an important decision-making tool in pts with lymphoma
andMM. Although Charlson and hematopoietic cell transplantation
CI (HCT-CI) were previously correlated with post-ASCT toxicities
and length of hospital stay in pts with MM, the groups with higher
scores included fewer pts, limiting study interpretation. We evalu-
ated the prognostic significance of HCT-CI on treatment-related
morbidity (as determined by changes in pulmonary function, length
of hospital stay, and 100-day readmission rate), overall (OS), and
progression-free survival (PFS). Our analysis included 85 consecu-
tive pts (median age, 57 yrs; 68% males) with MM who underwent
ASCT at our institution from 01/2009 to 12/2010. 59% of pts
were in first complete or partial remission prior to ASCT. 65% of
pts had received.1 prior therapy. Median time from diagnosis to
ASCT was 13.4 months. Melphalan-based preparative regimen was
used in 61 pts, whereas others received Bu/Cy on a clinical trial.
24.7% had HCT-CI of 0; 37.6% pts had scores of 1-2; 37.6% pts
had scores$3. Incremental HCT-CI groups were associated with
worse performance status (p\0.001), lower absolute and%predicted
pre-transplant FEV1 (98% vs. 90% vs. 86%, p 5 0.01), lower abso-
lute and % predicted pre-transplant DLCO (91% vs. 78% vs. 66%,
p\0.001), lower % predicted post-transplant DLCO (82% vs. 60%
vs. 75%, p\0.001), longer hospital stay (15 vs. 16 vs. 18 days, p 5
0.03), and faster platelet recovery (17 vs. 12 vs. 12 days, p 5 0.007).
With median follow up of 12 months, 12 pts were readmitted within
100-days of discharge, 12 pts died (9 relapses, 1 heart failure, 1 sepsis,
1 subdural hematoma) with 2 deaths within 100-days from ASCT,
and 12 pts progressed. None of the 3 non-relapse deaths occurred
in the lowest HCT-CI group (two inHCT-CI$3). HCT-CI groups
did not differ by pt readmissions, OS, PFS, and% changes in Pulmo-
nary Function Tests pre- and post-ASCT (all p.0.3). With over
a third of our study pts having HCT-CI$3, we detected no associa-
tion between higher HCT-CI scores and major clinical outcomes.
Our data demonstrate the safety of ASCT in pts with MM who
have higher pre-transplant HCT-CI.136
VINORELBINE-CYCLOPHOSPHAMIDE COMPARED TO CYCLOPHOSPHA-
MIDE IN PERIPHERAL BLOOD STEM CELL MOBILIZATION
Soh, T.G.1, de Mel, S.P.2, Tan, L.K.1 1National University Health Sys-
tem, Singapore, Singapore; 2National University Health System, Singa-
pore, Singapore
Background: High dose therapy followed by autologous stem cell
rescue is the standard of care for transplant eligible patients with
plasma cell myeloma. High dose cyclophosphamide (Cy) at 4-
7mg/m2 with granulocyte colony stimulating factor (GCSF) has
been shown to be an effective regimen for stem cell mobilization de-
spite associated haematologic toxicity. Vinorelbine 25mg/m2 in
